Drug Profile

DTP-poliovirus vaccine - KM Biologics

Alternative Names: Diphtheria tetanus pertussis and inactivated poliovirus vaccine - KM Biologics; Quattrovac

Latest Information Update: 06 Nov 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kaketsuken
Developer KM Biologics
Class Bacterial vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

01 Aug 2019 KM Biologics enters into a distribution agreement with Meiji Seika Pharma for its human vaccines portfolio (9307110; 9258921)
31 Jul 2019 Astellas Pharma and KM Biologics agreement for human vaccines expires (9307110; 9258921)
31 Oct 2012 Launched for Diphtheria in Japan (SC) - First global launch

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com